Floatz logo

68ganota-anti-mmr-vhh2

HLH

Universitair Ziekenhuis BrusselradiopharmaceuticalPhase 2Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the HLH cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Beijing Tongren Hospital
Phase 4BBB
PEGASPARGASE
Beijing Tongren Hospital
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 4BB
PEGASPARGASE
Zhengzhou University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Zhengzhou University
Phase 4BB

View all 33 →

Same molecule, other indications

68ganota-anti-mmr-vhh2 is also rated in:

cancerDormant
C
Indicative ·
36 / 100
View asset →
carotid stenosisDormant
C
Indicative ·
36 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →